Peter Bentham

7.1k total citations · 2 hit papers
63 papers, 3.2k citations indexed

About

Peter Bentham is a scholar working on Psychiatry and Mental health, Physiology and Pharmacology. According to data from OpenAlex, Peter Bentham has authored 63 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Psychiatry and Mental health, 14 papers in Physiology and 13 papers in Pharmacology. Recurrent topics in Peter Bentham's work include Dementia and Cognitive Impairment Research (21 papers), Alzheimer's disease research and treatments (13 papers) and Electroconvulsive Therapy Studies (9 papers). Peter Bentham is often cited by papers focused on Dementia and Cognitive Impairment Research (21 papers), Alzheimer's disease research and treatments (13 papers) and Electroconvulsive Therapy Studies (9 papers). Peter Bentham collaborates with scholars based in United Kingdom, Australia and United States. Peter Bentham's co-authors include Peter Crome, Claude M. Wischik, C Lendon, Damon Wischik, Wendy Hardyman, Jan R. Oyebode, Robert K. Hills, Roger T. Staff, Karin A. Kook and SJ Edwards and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Stroke.

In The Last Decade

Peter Bentham

61 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial

2004 612 citations Peter Bentham et al. The Lancet profile →
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

2016 321 citations Serge Gauthier, Howard Feldman et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Bentham United Kingdom	28	1.2k	989	707	455	381	63	3.2k
Jason T. Olin United States	34	2.5k 2.0×	1.3k 1.3×	1.3k 1.8×	431 0.9×	391 1.0×	79	5.1k
Howard Fillit United States	37	1.3k 1.0×	1.4k 1.4×	374 0.5×	577 1.3×	226 0.6×	124	4.2k
Rupert McShane United Kingdom	37	2.3k 1.9×	1.0k 1.0×	1.4k 2.0×	502 1.1×	537 1.4×	96	5.3k
Eva von Strauss Sweden	36	2.3k 1.9×	1.3k 1.3×	341 0.5×	899 2.0×	260 0.7×	77	5.4k
Christopher Ernesto United States	11	1.6k 1.3×	1.5k 1.6×	709 1.0×	223 0.5×	280 0.7×	11	3.6k
Elizabeth Rimmer United States	5	2.0k 1.6×	1.2k 1.2×	327 0.5×	762 1.7×	175 0.5×	9	4.2k
Alireza Atri United States	35	2.0k 1.6×	1.7k 1.7×	727 1.0×	242 0.5×	417 1.1×	119	5.0k
Naji Tabet United Kingdom	32	1.2k 1.0×	1.4k 1.4×	460 0.7×	250 0.5×	428 1.1×	98	4.0k
Jacques Touchon France	38	2.5k 2.1×	1.5k 1.5×	389 0.6×	260 0.6×	330 0.9×	100	5.0k
Richard Harvey United Kingdom	25	1.2k 1.0×	1.2k 1.2×	488 0.7×	187 0.4×	435 1.1×	56	3.3k

Countries citing papers authored by Peter Bentham

Since Specialization

Citations

This map shows the geographic impact of Peter Bentham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Bentham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Bentham more than expected).

Fields of papers citing papers by Peter Bentham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Bentham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Bentham. The network helps show where Peter Bentham may publish in the future.

Co-authorship network of co-authors of Peter Bentham

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Bentham. A scholar is included among the top collaborators of Peter Bentham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Bentham. Peter Bentham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wischik, Claude M., et al.. (2022). Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. The Journal of Prevention of Alzheimer s Disease. 9(4). 780–790. 28 indexed citations

Vuksanović, Vesna, Roger T. Staff, Trevor Ahearn, et al.. (2021). Degeneration of basal and limbic networks is a core feature of behavioural variant frontotemporal dementia. Brain Communications. 3(4). fcab241–fcab241. 4 indexed citations

Downs, Murna, et al.. (2020). A qualitative study exploring nursing home nurses’ experiences of training in person centred dementia care on burnout. Nurse Education in Practice. 44. 102745–102745. 6 indexed citations

Schelter, B., Thomas C. Baddeley, Christopher M. Rubino, et al.. (2019). Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease. Journal of Alzheimer s Disease. 72(3). 931–946. 33 indexed citations

Bentham, Peter, et al.. (2016). A qualitative study investigating training requirements of nurses working with people with dementia in nursing homes. Nurse Education Today. 50. 119–123. 35 indexed citations

Gauthier, Serge, Howard Feldman, Lon S. Schneider, et al.. (2016). Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. The Lancet. 388(10062). 2873–2884. 321 indexed citations breakdown →

Benavente-Pérez, Alexandra, Sunni R. Patel, Anil Negi, et al.. (2015). Retinal Microvascular Dysfunction occurs similarly in Alzheimer’s disease and Primary Open Angle Glaucoma patients. Investigative Ophthalmology & Visual Science. 56(7). 2763–2763. 1 indexed citations

Wischik, Claude M., Roger T. Staff, Damon Wischik, et al.. (2015). Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease. Journal of Alzheimer s Disease. 44(2). 705–720. 199 indexed citations

Benavente-Pérez, Alexandra, et al.. (2013). Retinal Vascular Dysfunction Relates to Cognitive Impairment in Alzheimer Disease. Alzheimer Disease & Associated Disorders. 28(4). 366–367. 10 indexed citations

10.

Leroi, Iracema, John Woolham, Robert Howard, et al.. (2013). Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial. Trials. 14(1). 349–349. 29 indexed citations

11.

Reilly, Thomas J., Roger T. Staff, Trevor Ahearn, et al.. (2011). Regional cerebral blood flow and aberrant motor behaviour in Alzheimer's disease. Behavioural Brain Research. 222(2). 375–379. 13 indexed citations

12.

Ballard, Clive, Richard G. Brown, Jane Fossey, et al.. (2009). Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial). American Journal of Geriatric Psychiatry. 17(9). 726–733. 62 indexed citations

13.

Pritchard, Antonia L., Laura E. Ratcliffe, Sayeed Haque, et al.. (2009). Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer's disease. International Journal of Geriatric Psychiatry. 24(9). 1020–1025. 18 indexed citations

14.

Staff, Roger T., et al.. (2008). P4‐347: Tau aggregation inhibitor (TAI) therapy with rember^™ arrests the trajectory of rCBF decline in brain regions affected by Tau pathology in mild and moderate Alzheimer's disease (AD). Alzheimer s & Dementia. 4(4S_Part_24). 9 indexed citations

15.

Chapuis, Julien, Didier Hannequin, Florence Pasquier, et al.. (2008). Association study of the GAB2 gene with the risk of developing Alzheimer's disease. Neurobiology of Disease. 30(1). 103–106. 27 indexed citations

16.

Howard, Robert, Edmund Juszczak, Clive Ballard, et al.. (2007). Donepezil for the Treatment of Agitation in Alzheimer's Disease. New England Journal of Medicine. 357(14). 1382–1392. 192 indexed citations

17.

Pritchard, Antonia L., Colin Pritchard, Peter Bentham, & Corinne Lendon. (2007). Role of Serotonin Transporter Polymorphisms in the Behavioural and Psychological Symptoms in Probable Alzheimer Disease Patients. Dementia and Geriatric Cognitive Disorders. 24(3). 201–206. 52 indexed citations

18.

Pritchard, Antonia L., Jessica Harris, Colin Pritchard, et al.. (2006). The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer's disease. Journal of Neurology Neurosurgery & Psychiatry. 78(2). 123–126. 44 indexed citations

19.

Morris, A., et al.. (2002). A Dental Risk Management Protocol for Electroconvulsive Therapy. Journal of Ect. 18(2). 84–89. 8 indexed citations

20.

Bryan, Stirling, et al.. (2001). EQ-5D in Patients With Dementia An Investigation of Inter-Rater Agreement. Medical Care. 39(8). 760–771. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact